Stuart Therapeutics, Inc. (Stuart) has announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,684,651, with granted claims for compositions of matter and methods of use in a variety of anterior segment indications in ophthalmology.
|
[08-September-2023] |
Stuart Expands its Patent Portfolio to 10 Granted Patents and 32 Pending Patent Applications STUART, Fla., Sept. 8, 2023 /PRNewswire/ -- Stuart Therapeutics, Inc. (Stuart), a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, has announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,684,651, with granted claims for compositions of matter and methods of use in a variety of anterior segment indications in ophthalmology. Stuart Therapeutics, Inc. Expands its Patent Portfolio Stuart now controls a total of 10 granted patents, including 5 in the United States, with an additional 32 patents currently pending in the US and other countries. The patents support a growing body of intellectual property supporting the PolyCol™ (PolyCol) platform of Collagen Mimetic Peptide (CMP) therapeutic compounds. This family of peptides is designed to mimic natural collagen fragments, and certain of these peptides have been shown in both pre-clinical testing and clinical trial settings to provide an improvement in diseased and damaged tissues, including those tissues comprising epithelial cells and neuronal cells. The CMP mechanism of action repairs disease damaged structural and extracellular matrix collagen, acting to restore homeostatic cell signaling, improving the cellular microenvironment and reducing inflammation. Stuart controls the rights to this technology for human therapeutic use in ophthalmology through a prior agreement with the patent owner, Sustain Holdings, LLC. The newly granted patent claims expand Stuart’s intellectual property in ophthalmic anterior segment diseases and disorders. Stuart is currently developing PolyCol sequences for dry eye disease (entering Phase 3 clinical trials in 4Q, 2023), glaucoma, retinal diseases and disorders, and myopia. About Stuart Therapeutics, Inc. CONTACT: Eric Schlumpf, President & CEO View original content to download multimedia:https://www.prnewswire.com/news-releases/stuart-therapeutics-announces-issuance-of-us-patent-covering-ophthalmic-anterior-segment-disorders-301922051.html SOURCE Stuart Therapeutics |